MX2016003643A - Anticuerpo anti-lps o11. - Google Patents

Anticuerpo anti-lps o11.

Info

Publication number
MX2016003643A
MX2016003643A MX2016003643A MX2016003643A MX2016003643A MX 2016003643 A MX2016003643 A MX 2016003643A MX 2016003643 A MX2016003643 A MX 2016003643A MX 2016003643 A MX2016003643 A MX 2016003643A MX 2016003643 A MX2016003643 A MX 2016003643A
Authority
MX
Mexico
Prior art keywords
lps
antibody
pseudomonas aeruginosa
antibacterial activity
drug composition
Prior art date
Application number
MX2016003643A
Other languages
English (en)
Inventor
Hasegawa Jun
Sugihara Kiyoshi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2016003643A publication Critical patent/MX2016003643A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

El propósito de la presente invención es proporcionar una sustancia que tenga una actividad antibacteriana excepcional contra Pseudomonas aeruginosa y una composición de fármaco para el tratamiento y/o prevención de las infecciones por pseudomonas. Se proporciona una composición de fármaco que contiene un anticuerpo que se une específicamente al antígeno LPS O11 de Pseudomonas aeruginosa y que tiene actividad antibacteriana excepcional.
MX2016003643A 2013-09-30 2014-09-29 Anticuerpo anti-lps o11. MX2016003643A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013203297 2013-09-30
PCT/JP2014/075866 WO2015046505A1 (ja) 2013-09-30 2014-09-29 抗ｌｐｓ ｏ１１抗体

Publications (1)

Publication Number Publication Date
MX2016003643A true MX2016003643A (es) 2016-12-20

Family

ID=52743628

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003643A MX2016003643A (es) 2013-09-30 2014-09-29 Anticuerpo anti-lps o11.

Country Status (16)

Country Link
US (1) US9951123B2 (es)
EP (2) EP3835422A1 (es)
JP (1) JP6494519B6 (es)
KR (1) KR20160062009A (es)
CN (1) CN105849262A (es)
AU (1) AU2014325023A1 (es)
BR (1) BR112016006428A2 (es)
CA (1) CA2925897A1 (es)
IL (1) IL244823A0 (es)
MX (1) MX2016003643A (es)
PH (1) PH12016500576A1 (es)
RU (1) RU2016116949A (es)
SG (1) SG11201602490UA (es)
TW (1) TW201602341A (es)
WO (1) WO2015046505A1 (es)
ZA (1) ZA201602533B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3374391B1 (en) 2015-11-10 2024-04-17 Visterra, Inc. Antibody molecule-drug conjugates that specifically binds to lipopolysaccharide and uses thereof
EP4159749A3 (en) 2016-07-01 2023-06-14 Daiichi Sankyo Company, Limited A method for producing fc-containing molecule with remodeled sugar chain
US11890319B2 (en) 2017-01-18 2024-02-06 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
WO2018187512A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
CN107843731B (zh) * 2017-09-14 2020-01-03 北京牛牛基因技术有限公司 一种检测外周血中胰腺癌细胞标志物的试剂盒
CN116999573A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体－药物偶联物及其制造方法、药物组合物及其在制备治疗肿瘤的药物中的应用
AU2019379418A1 (en) 2018-11-14 2021-06-03 Daiichi Sankyo Company, Limited Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate
CN109912717B (zh) * 2019-03-04 2020-05-26 北京天广实生物技术股份有限公司 结合cd40的抗体及其用途
KR20210143237A (ko) 2019-03-25 2021-11-26 다이이찌 산쿄 가부시키가이샤 항체-피롤로벤조디아제핀 유도체 컨쥬게이트
US20220275065A1 (en) * 2019-07-31 2022-09-01 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
EP4126064A1 (en) 2020-04-03 2023-02-08 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
JP2024503658A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗ｄｌｌ３抗体－薬物コンジュゲート
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH04211393A (ja) 1990-02-08 1992-08-03 Sumitomo Pharmaceut Co Ltd ヒトモノクローナル抗体及びそれを有効成分とする緑膿菌感染症治療剤
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
CN1101404C (zh) * 1998-07-29 2003-02-12 中德联合研究院 抗绿脓杆菌卵黄免疫球蛋白的产品及其应用
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
WO2005056601A2 (en) * 2003-12-05 2005-06-23 Schreiber John R Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
CA2785941C (en) 2000-10-06 2017-01-10 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
PT1583830E (pt) 2003-01-07 2006-11-30 Symphogen As Método para produzir proteínas policlonais recombinantes
EP1690875A1 (en) * 2005-02-14 2006-08-16 Kenta Biotech AG Human monoclonal antibody specific for lipopolysaccharides (LPS) of the pseudomonas aeruginosa IATS O11 serotype
WO2009048072A1 (ja) 2007-10-11 2009-04-16 Daiichi Sankyo Company, Limited 破骨細胞関連蛋白質Ｓｉｇｌｅｃ－１５を標的とした抗体
US8993241B2 (en) 2008-01-18 2015-03-31 National University Corporation University Of Toyama Reaction device, reaction method and method of synthesizing cDNA
AU2010222150B2 (en) * 2009-03-11 2015-07-16 Shionogi & Co. Ltd. Humanized PcrV antibody having anti-Pseudomonal activity
KR101690340B1 (ko) 2009-04-09 2016-12-27 다이이찌 산쿄 가부시키가이샤 항 Ｓｉｇｌｅｃ-15 항체
AU2010290426B2 (en) 2009-09-04 2014-12-11 National University Corporation University Of Toyama Method for specifically producing a joined DNA fragment comprising a sequence derived from a target gene
JP2013521759A (ja) 2010-02-18 2013-06-13 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 緑膿菌の血清型ｂ型リポ多糖に対する抗体
WO2012133572A1 (ja) 2011-03-30 2012-10-04 国立大学法人富山大学 形質細胞または形質芽細胞の選択方法、目的抗原特異的な抗体の製造方法、新規モノクローナル抗体

Also Published As

Publication number Publication date
EP3835422A1 (en) 2021-06-16
WO2015046505A1 (ja) 2015-04-02
JPWO2015046505A1 (ja) 2017-03-09
RU2016116949A (ru) 2017-11-10
JP6494519B2 (ja) 2019-04-03
AU2014325023A1 (en) 2016-04-28
BR112016006428A2 (pt) 2017-09-26
PH12016500576A1 (en) 2016-06-13
AU2014325023A2 (en) 2016-05-26
CA2925897A1 (en) 2015-04-02
EP3061818A4 (en) 2017-05-03
EP3061818A1 (en) 2016-08-31
ZA201602533B (en) 2017-07-26
IL244823A0 (en) 2016-05-31
SG11201602490UA (en) 2016-04-28
JP6494519B6 (ja) 2019-07-31
TW201602341A (zh) 2016-01-16
CN105849262A (zh) 2016-08-10
WO2015046505A8 (ja) 2015-05-21
KR20160062009A (ko) 2016-06-01
US9951123B2 (en) 2018-04-24
US20160311892A1 (en) 2016-10-27
EP3061818B1 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
PH12016500576A1 (en) Anti-lps o11 antibody
CY1123552T1 (el) Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA201991523A1 (ru) Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам
PH12016500207A1 (en) Anti-infective compounds
BR112015010240A2 (pt) Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
EP3702372A3 (en) Anti-cd40 human antibodies
MX2020003581A (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas.
EA201691488A1 (ru) Молекулы антител против pd-1 и их применения
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
MY177774A (en) Anti-wall teichoic antibodies and conjugates
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2017007055A (es) Conjugados de anticuerpo rifamicina anti-staphylococcus aureus y usos de estos.
MX2015016354A (es) Anticuerpos anti-acido teicoico de pared y conjugados.
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
WO2015003816A3 (en) Cystobactamides
PE20161032A1 (es) Anticuerpos anti-tau(ps422) humanizados y metodos de utilizacion
BR112017011478A2 (pt) composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
TW201613575A (en) Treatment of polybacterial infections
CL2016000568A1 (es) Compuestos derivados de 2h-indazol-2-il-n-hidroxi-2-metilsulfonil-2-metil-butanamida sustituidos o sus sales; sus composiciones farmacéuticas que los contiene y su uso para la prevención y/o tratamiento de infecciones bacterianas gram-negativas.
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EP3492101A3 (en) Agents for influenza neutralization
PH12016501988A1 (en) Antibacterial compounds